ATE544453T1 - Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionen - Google Patents
Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionenInfo
- Publication number
- ATE544453T1 ATE544453T1 AT03764562T AT03764562T ATE544453T1 AT E544453 T1 ATE544453 T1 AT E544453T1 AT 03764562 T AT03764562 T AT 03764562T AT 03764562 T AT03764562 T AT 03764562T AT E544453 T1 ATE544453 T1 AT E544453T1
- Authority
- AT
- Austria
- Prior art keywords
- fmau
- hepatitis
- treatment
- combination therapies
- virus infections
- Prior art date
Links
- 241000700721 Hepatitis B virus Species 0.000 title abstract 2
- GBBJCSTXCAQSSJ-XQXXSGGOSA-N clevudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1[C@H](F)[C@@H](O)[C@H](CO)O1 GBBJCSTXCAQSSJ-XQXXSGGOSA-N 0.000 title abstract 2
- 208000029433 Herpesviridae infectious disease Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 102000006992 Interferon-alpha Human genes 0.000 abstract 1
- 108010047761 Interferon-alpha Proteins 0.000 abstract 1
- 102000008070 Interferon-gamma Human genes 0.000 abstract 1
- 108010074328 Interferon-gamma Proteins 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 229960003130 interferon gamma Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39611702P | 2002-07-15 | 2002-07-15 | |
| PCT/US2003/021811 WO2004006843A2 (en) | 2002-07-15 | 2003-07-11 | Combination therapies with l-fmau for the treatment of hepatitis b virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE544453T1 true ATE544453T1 (de) | 2012-02-15 |
Family
ID=30115974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03764562T ATE544453T1 (de) | 2002-07-15 | 2003-07-11 | Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionen |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20050196379A1 (de) |
| EP (1) | EP1545557B1 (de) |
| JP (1) | JP4806187B2 (de) |
| KR (2) | KR20110031250A (de) |
| CN (1) | CN100536852C (de) |
| AT (1) | ATE544453T1 (de) |
| AU (2) | AU2003253888A1 (de) |
| CA (1) | CA2492554A1 (de) |
| ES (1) | ES2381266T3 (de) |
| SG (1) | SG165996A1 (de) |
| WO (2) | WO2004006843A2 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004051804A1 (de) * | 2004-10-21 | 2006-04-27 | Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) | Beta-L-N4-Hydroxycytosin-Desoxynucleoside und ihre Verwendung als pharmazeutische Mittel zur Prophylaxe oder Therapie von viralen Erkrankungen |
| PH12012502210A1 (en) * | 2010-05-18 | 2013-02-04 | Bukwang Pharma Co Ltd | Composition for treating chronic hepatitis b, containing clevudine and adefovir dipivoxil |
| RU2595862C2 (ru) * | 2013-09-03 | 2016-08-27 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Способ профилактики или лечения заболеваний, связанных с пониженной плотностью интерфероновых рецепторов |
| WO2016106050A1 (en) | 2014-12-26 | 2016-06-30 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| RU2020116571A (ru) | 2017-12-07 | 2021-11-22 | Эмори Юниверсити | N4-гидроксицитидин и производные и связанные с этим противовирусные применения |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL76591A0 (en) * | 1984-10-05 | 1986-02-28 | Bioferon Biochem Substanz | Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof |
| GB9110874D0 (en) * | 1991-05-20 | 1991-07-10 | Iaf Biochem Int | Medicaments |
| US5703058A (en) * | 1995-01-27 | 1997-12-30 | Emory University | Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent |
| WO1998055609A1 (en) * | 1997-06-06 | 1998-12-10 | The Regents Of The University Of California | Inhibitors of dna immunostimulatory sequence activity |
| IL142910A0 (en) * | 1998-11-02 | 2002-04-21 | Triangle Pharmaceuticals Inc | Combination therapy to treat hepatitis b virus |
| GB2355932B (en) * | 1999-04-12 | 2004-01-07 | Univ Madras | A pharmaceutical formulation suitable for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation |
| CA2404041A1 (en) * | 2000-03-28 | 2001-10-04 | The Regents Of The University Of California | Methods for increasing a cytotoxic t lymphocyte response in vivo |
-
2003
- 2003-07-11 KR KR1020117005008A patent/KR20110031250A/ko not_active Ceased
- 2003-07-11 WO PCT/US2003/021811 patent/WO2004006843A2/en not_active Ceased
- 2003-07-11 SG SG200702805-3A patent/SG165996A1/en unknown
- 2003-07-11 KR KR1020057000769A patent/KR20050042134A/ko not_active Abandoned
- 2003-07-11 AT AT03764562T patent/ATE544453T1/de active
- 2003-07-11 ES ES03764562T patent/ES2381266T3/es not_active Expired - Lifetime
- 2003-07-11 EP EP03764562A patent/EP1545557B1/de not_active Expired - Lifetime
- 2003-07-11 AU AU2003253888A patent/AU2003253888A1/en not_active Abandoned
- 2003-07-11 JP JP2004521734A patent/JP4806187B2/ja not_active Expired - Fee Related
- 2003-07-11 CN CNB038218771A patent/CN100536852C/zh not_active Expired - Fee Related
- 2003-07-11 US US10/618,531 patent/US20050196379A1/en not_active Abandoned
- 2003-07-11 CA CA002492554A patent/CA2492554A1/en not_active Abandoned
- 2003-07-15 WO PCT/US2003/021929 patent/WO2004006848A2/en not_active Ceased
- 2003-07-15 AU AU2003253894A patent/AU2003253894A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004006848A2 (en) | 2004-01-22 |
| EP1545557B1 (de) | 2012-02-08 |
| AU2003253894A1 (en) | 2004-02-02 |
| KR20050042134A (ko) | 2005-05-04 |
| WO2004006843A3 (en) | 2004-07-22 |
| CN100536852C (zh) | 2009-09-09 |
| SG165996A1 (en) | 2010-11-29 |
| ES2381266T3 (es) | 2012-05-24 |
| AU2003253888A8 (en) | 2004-02-02 |
| JP2005538084A (ja) | 2005-12-15 |
| AU2003253888A1 (en) | 2004-02-02 |
| KR20110031250A (ko) | 2011-03-24 |
| JP4806187B2 (ja) | 2011-11-02 |
| CN1681518A (zh) | 2005-10-12 |
| WO2004006843A2 (en) | 2004-01-22 |
| US20050196379A1 (en) | 2005-09-08 |
| AU2003253894A8 (en) | 2004-02-02 |
| WO2004006848A3 (en) | 2004-12-16 |
| EP1545557A2 (de) | 2005-06-29 |
| CA2492554A1 (en) | 2004-01-22 |
| EP1545557A4 (de) | 2009-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE475423T1 (de) | Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen | |
| EA200700243A1 (ru) | Способы лечения гепатита с | |
| AR045870A1 (es) | Terapia de combinacion para la infeccion de virus de hepatitis c | |
| CY1110437T1 (el) | Χρηση παραγωγων καστανοσπερμινης για την θεραπεια της ηπατιτιδας c | |
| MXPA02012443A (es) | Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos. | |
| DE60321929D1 (de) | Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen | |
| DK1368060T3 (da) | HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme | |
| ATE495739T1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
| EA200000911A1 (ru) | Новые кристаллические формы антивирусного соединения бензимидазола | |
| DE60330708D1 (de) | Impfstoff gegen das west-nile-virus | |
| ATE427116T1 (de) | Behandlung von bakteriellen infektionen | |
| MXPA04006572A (es) | Terapia de combinacion antivirica. | |
| NO20052136L (no) | Vaksine mot Hepatitt C-virus (HCV). | |
| ATE486634T1 (de) | Caspase 3, 8, 9 oder 10 inhibitoren in kombination mit mek inhibitoren zur behandlung von influenza | |
| ATE375786T1 (de) | Chitin-mikropartikel und ihre medizinische verwendung | |
| ATE415961T1 (de) | Therapeutische verwendung von mitgliedern der n,n-dicylcohexyl-2-hydroxy-7,7- dimethylbicycloä2.2.1ühept-1- ylmethanesulphonamide-familie | |
| ATE520412T1 (de) | Therapien für chronisch inflammatorische demyelinisierende polyradikuoneuropathie mit interferon-beta | |
| AU2003253888A8 (en) | Combination therapies with l-fmau for the treatment of hepatitis b virus infection | |
| DK0768886T3 (da) | Endothelforingseffekter og behandling af vasospastiske lidelser | |
| ATE468130T1 (de) | Inhibitoren der kostimulation via ox40 und deren verwendung gegen eine von virusen induzierten immunpathologie | |
| DE602005016552D1 (de) | Parapocken-viren in kombination mit anderen antiviralen mitteln zur behandlung von hiv/aids | |
| ATE255594T1 (de) | Hepatitis b inhibitoren | |
| MXPA05007901A (es) | Terapia de combinacion para hcv. | |
| AU2003302275A8 (en) | Bicyclic carbohydrate compounds useful in the treatment of infections caused by flaviviridae sp., such as hepatitis c and bovine viral diarrhea viruses | |
| DE60002172D1 (de) | Verwendung von (1r,4s)-4-(6-amino-9h-purin-9-yl)-2-cyclopenten-1-methanol in hbv |